The European Commission has adopted a decision to change the Repatha (evolocumab) marketing authorization, approving a new single-dose delivery option. Read More »

Amgen and Novartis are working together to fight against migraines with erenumab, an expanded commercial collaboration building on a global neuroscience collaboration in Alzheimer's disease and migraine established in 2015. Read More »

Amgen recently announced that a planned overall survival (OS) interim analysis of the Phase 3 head-to-head Endeavor trial delivered positive results. Read More »

Bedside delivery of medications is a practice that is helping patients live more healthily following discharge from hospitals. Read More »

Amgen recently unveiled new data from the Kyprolis and Xgeva clinical development programs at the 16th International Myeloma Workshop in New Delhi. Read More »

Amgen's results from its Phase 3 Tower study evaluating Blincyto’s efficacy have been published in the New England Journal of Medicine. Read More »

Amgen and UCB recently announced that their phase 2 study for Evenity (romosozumab) showed positive fourth-year results for efficacy and safety as a second course of treatment for postmenopausal women with osteoporosis. Read More »

Amgen recently announced that the company submitted to the U.S. Food and Drug Administration (FDA) a supplemental Biologics License Application (sBLA) for Xgeva (denosumab). The company also seeks approval from the European Medicines Agency (EMA). Read More »

Amgen's esults from its Phase 2, open-label ALCANTARA study evaluating the efficacy and safety of BLINCYTO has been published in the Journal of Clinical Oncology. Read More »

Based on 27,564 patient cardiovascular outcomes study, Amgen has established that maximally reducing low-density lipoprotein cholesterol levels with Repatha leads to a further reduction in major cardiovascular events, including heart attacks, strokes and coronary revascularizations. Read More »

Amgen recently announced that the European Commission (EC) granted the company authorization to bring to market Amgevita in all available indications. Read More »

Amgen's data from two studies shows that for appropriate patients in the United States, the majority of prescription claims for PCSK9 inhibitors, such as Repatha (evolocumab), were initially rejected. Read More »

Amgen recently announced the results of the Repatha (evolocumab) cognitive function trial that examined cognitive function for 1,974 patients enrolled in the Repatha cardiovascular outcomes study. Read More »

Amgen recently announced positive data from the Phase 3 '482 study, which is the largest international multiple myeloma trial ever conducted. Read More »

Amgen's positive results from a planned overall survival interim analysis of the Phase 3 head-to-head ENDEAVOR trial. Read More »

Amgen’s recent Phase 3 study of the effects of Repatha on patients who receive apheresis for low-density lipoprotein cholesterol showed a promising reduction in the need for the recurring procedure. Read More »

The results from Amgen’s four-year follow up OSLER-1 study on Repatha, which is so far the longest PCSK9 inhibitor clinical trial, were recently published in JAMA Cardiology. Read More »

Amgen's results of its Repatha (evolocumab) cardiovascular outcomes trial will be released at the American College of Cardiology's 66th Annual Scientific Session, which is set to take place in Washington, D.C. March 17-19. Read More »

Synergy Pharmacy Services recently received its Pharmacy Compounding Accreditation Board accreditation, which classifies it as a company that follows the highest quality and safety standards in the industry. Read More »

Biotech company Amgen submitted an application to the U.S. Food and Drug Administration for Blincyto, a drug used in the treatment of lymphoblastic leukemia, to broaden its uses and treatments. Read More »